These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 37207587)
1. Targeted delivery of temozolomide by nanocarriers based on folic acid-hollow TiO Uribe-Robles M; Ortiz-Islas E; Rodriguez-Perez E; Valverde FF; Lim T; Martinez-Morales AA Biomater Adv; 2023 Aug; 151():213442. PubMed ID: 37207587 [TBL] [Abstract][Full Text] [Related]
2. Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells. Dastghaib S; Shojaei S; Mostafavi-Pour Z; Sharma P; Patterson JB; Samali A; Mokarram P; Ghavami S Cells; 2020 Oct; 9(11):. PubMed ID: 33105603 [TBL] [Abstract][Full Text] [Related]
3. Angiopep-2 Grafted PAMAM Dendrimers for the Targeted Delivery of Temozolomide: Sahoo RK; Kumar H; Jain V; Sinha S; Ajazuddin ; Gupta U ACS Biomater Sci Eng; 2023 Jul; 9(7):4288-4301. PubMed ID: 37307155 [TBL] [Abstract][Full Text] [Related]
4. Tri-block copolymer nanoparticles modified with folic acid for temozolomide delivery in glioblastoma. Emamgholizadeh Minaei S; Khoei S; Khoee S; Karimi MR Int J Biochem Cell Biol; 2019 Mar; 108():72-83. PubMed ID: 30660689 [TBL] [Abstract][Full Text] [Related]
5. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214 [TBL] [Abstract][Full Text] [Related]
6. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Kim SS; Rait A; Kim E; Pirollo KF; Chang EH Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597 [TBL] [Abstract][Full Text] [Related]
7. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2. Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898 [TBL] [Abstract][Full Text] [Related]
8. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
10. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
11. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway. Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746 [TBL] [Abstract][Full Text] [Related]
12. In vitro anti-cancer efficacy of multi-functionalized magnetite nanoparticles combining alternating magnetic hyperthermia in glioblastoma cancer cells. Minaei SE; Khoei S; Khoee S; Vafashoar F; Mahabadi VP Mater Sci Eng C Mater Biol Appl; 2019 Aug; 101():575-587. PubMed ID: 31029351 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. Liang H; Chen Z; Sun L Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274 [TBL] [Abstract][Full Text] [Related]
14. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036 [TBL] [Abstract][Full Text] [Related]
16. Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy. Kadhim ZA; Sulaiman GM; Al-Shammari AM; Khan RA; Al Rugaie O; Mohammed HA Molecules; 2022 Sep; 27(18):. PubMed ID: 36144488 [TBL] [Abstract][Full Text] [Related]
17. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. Yasaswi PS; Shetty K; Yadav KS J Control Release; 2021 Aug; 336():549-571. PubMed ID: 34229001 [TBL] [Abstract][Full Text] [Related]
18. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle. Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038 [TBL] [Abstract][Full Text] [Related]
19. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma. Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758 [TBL] [Abstract][Full Text] [Related]
20. High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. Lee JE; Lim JH; Hong YK; Yang SH Cancer Res Treat; 2018 Oct; 50(4):1331-1342. PubMed ID: 29334602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]